Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

Nicole A. Carreau, Orrin Pail, Philippe Armand, Reid Merryman, Ranjana H. Advani, Michael A. Spinner, Alex Herrera, Robert Chen, Sarah Tomassetti, Radhakrishnan Ramchandren, Muhammad S. Hamid, Sarit Assouline, Raoul Santiago, Nina Wagner-Johnston, Suman Paul, Jakub Svoboda, Steven Bair, Stefan Barta, Yang Liu, Sunita NathanReem Karmali, Madelyn Burkart, Pallawi Torka, Kevin David, Catherine Wei, Frederick Lansigan, Lukas Emery, Daniel Persky, Sonali Smith, James Godfrey, Julio Chavez, Yuhe Xia, Andrea B. Troxel, Catherine Diefenbach

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further therapies will be. Moreover, there are no data on optimal sequencing of these treatments with standard therapies and other novel agents. In a multicenter, retrospective analysis, we investigated whether exposure to CBT could sensitize HL to subsequent therapy. Materials and Methods: Seventeen centers across the U.S. and Canada retrospectively queried medical records for eligible patients. The primary aim was to evaluate the overall response rate (ORR) to post-CBT treatment using the Lugano criteria. Secondary aims included progression-free survival (PFS), duration of response, and overall survival (OS). Results: Eighty-one patients were included. Seventy-two percent had stage III–IV disease, and the population was heavily pretreated with a median of four therapies before CBT. Most patients (65%) discontinued CBT owing to progression. The ORR to post-CBT therapy was 62%, with a median PFS of 6.3 months and median OS of 21 months. Post-CBT treatment regimens consisted of chemotherapy (44%), targeted agents (19%), immunotherapy (15%), transplant conditioning (14%), chemotherapy/targeted combination (7%), and clinical trials (1%). No significant difference in OS was found when stratified by post-CBT regimen. Conclusion: In a heavily pretreated R/R HL population, CBT may sensitize patients to subsequent treatment, even after progression on CBT. Post-CBT regimen category did not impact OS. This may be a novel treatment strategy, which warrants further investigation in prospective clinical trials. Implications for Practice: Novel, life-prolonging treatment strategies in relapsed and refractory (R/R) Hodgkin lymphoma (HL) are greatly desired. The results of this multicenter analysis concur with a smaller, earlier report that checkpoint blockade therapy (CBT) use in R/R HL may sensitize patients to their subsequent treatment. This approach may potentially enhance therapeutic options or to bridge patients to transplant. Prospective data are warranted prior to practice implementation. As more work is done in this area, we may also be able to optimize sequencing of CBT and novel agents in the treatment paradigm to minimize treatment-related toxicity and thus improve patient quality of life.

Original languageEnglish (US)
Pages (from-to)878-885
Number of pages8
JournalOncologist
Volume25
Issue number10
DOIs
StatePublished - Oct 1 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Checkpoint blockade
  • Hodgkin lymphoma
  • Immunotherapy
  • Relapsed
  • Sensitization

Fingerprint

Dive into the research topics of 'Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy'. Together they form a unique fingerprint.

Cite this